Predictors of survival in autoimmune liver disease overlap syndromes.

IF 2.5 Q2 GASTROENTEROLOGY & HEPATOLOGY World Journal of Hepatology Pub Date : 2024-09-27 DOI:10.4254/wjh.v16.i9.1269
Dujinthan Jayabalan, Yi Huang, Luis Calzadilla-Bertot, Malik Janjua, Bastiaan de Boer, John Joseph, Wendy Cheng, Simon Hazeldine, Briohny W Smith, Gerry C MacQuillan, Michael C Wallace, George Garas, Leon A Adams, Gary P Jeffrey
{"title":"Predictors of survival in autoimmune liver disease overlap syndromes.","authors":"Dujinthan Jayabalan, Yi Huang, Luis Calzadilla-Bertot, Malik Janjua, Bastiaan de Boer, John Joseph, Wendy Cheng, Simon Hazeldine, Briohny W Smith, Gerry C MacQuillan, Michael C Wallace, George Garas, Leon A Adams, Gary P Jeffrey","doi":"10.4254/wjh.v16.i9.1269","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Survival in patients with autoimmune liver disease overlap syndromes (AILDOS) compared to those with single autoimmune liver disease is unclear.</p><p><strong>Aim: </strong>To investigate the survival of patients with AILDOS and assess the accuracy of non-invasive serum models for predicting liver-related death.</p><p><strong>Methods: </strong>Patients with AILDOS were defined as either autoimmune hepatitis and primary biliary cholangitis overlap (AIH-PBC) or autoimmune hepatitis and primary sclerosing cholangitis overlap (AIH-PSC) and were identified from three tertiary centres for this cohort study. Liver-related death or transplantation (liver-related mortality) was determined using a population-based data linkage system. Prognostic scores for liver-related death were compared for accuracy [including liver outcome score (LOS), Hepascore, Mayo Score, model for end-stage liver disease (MELD) score and MELD incorporated with serum sodium (MELD-Na) score].</p><p><strong>Results: </strong>Twenty-two AILDOS patients were followed for a median of 3.1 years (range, 0.35-7.7). Fourteen were female, the median age was 46.7 years (range, 17.8 to 82.1) and median Hepascore was 1 (range, 0.07-1). At five years post enrolment, 57% of patients remained free from liver-related mortality (74% AIH-PBC, 27% AIH-PSC). There was no significant difference in survival between AIH-PBC and AIH-PSC. LOS was a significant predictor of liver-related mortality (<i>P</i> < 0.05) in patients with AIH-PBC (<i>n</i> = 14) but not AIH-PSC (<i>n</i> = 8). A LOS cut-point of 6 discriminated liver-related mortality in AIH-PBC patients (<i>P</i> = 0.012, log-rank test, 100% sensitivity, 77.8% specificity) (Harrell's C-statistic 0.867). The MELD score, MELD-Na score and Mayo Score were not predictive of liver-related mortality in any group.</p><p><strong>Conclusion: </strong>Survival in the rare, AILDOS is unclear. The current study supports the LOS as a predictor of liver-related mortality in AIH-PBC patients. Further trials investigating predictors of survival in AILDOS are required.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438591/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4254/wjh.v16.i9.1269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Survival in patients with autoimmune liver disease overlap syndromes (AILDOS) compared to those with single autoimmune liver disease is unclear.

Aim: To investigate the survival of patients with AILDOS and assess the accuracy of non-invasive serum models for predicting liver-related death.

Methods: Patients with AILDOS were defined as either autoimmune hepatitis and primary biliary cholangitis overlap (AIH-PBC) or autoimmune hepatitis and primary sclerosing cholangitis overlap (AIH-PSC) and were identified from three tertiary centres for this cohort study. Liver-related death or transplantation (liver-related mortality) was determined using a population-based data linkage system. Prognostic scores for liver-related death were compared for accuracy [including liver outcome score (LOS), Hepascore, Mayo Score, model for end-stage liver disease (MELD) score and MELD incorporated with serum sodium (MELD-Na) score].

Results: Twenty-two AILDOS patients were followed for a median of 3.1 years (range, 0.35-7.7). Fourteen were female, the median age was 46.7 years (range, 17.8 to 82.1) and median Hepascore was 1 (range, 0.07-1). At five years post enrolment, 57% of patients remained free from liver-related mortality (74% AIH-PBC, 27% AIH-PSC). There was no significant difference in survival between AIH-PBC and AIH-PSC. LOS was a significant predictor of liver-related mortality (P < 0.05) in patients with AIH-PBC (n = 14) but not AIH-PSC (n = 8). A LOS cut-point of 6 discriminated liver-related mortality in AIH-PBC patients (P = 0.012, log-rank test, 100% sensitivity, 77.8% specificity) (Harrell's C-statistic 0.867). The MELD score, MELD-Na score and Mayo Score were not predictive of liver-related mortality in any group.

Conclusion: Survival in the rare, AILDOS is unclear. The current study supports the LOS as a predictor of liver-related mortality in AIH-PBC patients. Further trials investigating predictors of survival in AILDOS are required.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
自身免疫性肝病重叠综合征的生存预测因素。
背景:目的:调查自身免疫性肝病重叠综合征(AILDOS)患者的生存情况,并评估非侵入性血清模型预测肝脏相关死亡的准确性:方法:AILDOS患者被定义为自身免疫性肝炎与原发性胆汁性胆管炎重叠(AIH-PBC)或自身免疫性肝炎与原发性硬化性胆管炎重叠(AIH-PSC),并从三个三级中心确定了这些患者进行队列研究。肝脏相关死亡或移植(肝脏相关死亡率)是通过基于人口的数据链接系统确定的。对肝脏相关死亡的预后评分(包括肝脏预后评分(LOS)、Hepascore、梅奥评分、终末期肝病模型(MELD)评分和MELD合并血清钠(MELD-Na)评分)的准确性进行了比较:对 22 名 AILDOS 患者进行了中位 3.1 年(0.35-7.7 年)的随访。其中 14 名患者为女性,年龄中位数为 46.7 岁(范围为 17.8 至 82.1 岁),肝功能评分中位数为 1(范围为 0.07-1)。入组五年后,57%的患者仍未出现与肝脏相关的死亡(74%为AIH-PBC,27%为AIH-PSC)。AIH-PBC和AIH-PSC的存活率没有明显差异。LOS是AIH-PBC患者(14人)而非AIH-PSC患者(8人)肝脏相关死亡率的重要预测因素(P<0.05)。6分的LOS切点可判别AIH-PBC患者的肝脏相关死亡率(P = 0.012,对数秩检验,敏感性100%,特异性77.8%)(Harrell's C统计量0.867)。MELD评分、MELD-Na评分和梅奥评分在任何组别中都不能预测肝脏相关死亡率:结论:罕见的 AILDOS 的存活率尚不明确。目前的研究支持将 LOS 作为 AIH-PBC 患者肝脏相关死亡率的预测指标。需要进行更多试验来研究 AILDOS 的生存预测因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
World Journal of Hepatology
World Journal of Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
4.10
自引率
4.20%
发文量
172
期刊最新文献
Chronic hepatitis B: Prevent, diagnose, and treat before the point of no return. Complement activation targeted inhibitor C2-FH ameliorates acetaminophen-induced liver injury in mice. Hepatitis B surface antigen-negative but hepatitis B envelope antigen-positive false occult hepatitis B virus infection: A case report. Liver cell cancer surveillance practice in Nigeria: Pitfalls and future prospects. Pathogenesis and research progress of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1